Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    TCR2 Therapeutics Inc.

    NASDAQ: TCRR · Real-Time Price · USD
    1.48
    0.00 (0.00%)
    At close: May 31, 2023, 8:00 PM

    TCR2 Therapeutics Statistics

    Share Statistics

    TCR2 Therapeutics has 39.26M shares outstanding. The number of shares has increased by 0% in one year.

    Shares Outstanding

    n/a
    		 39.26M

    Shares Change (YoY)

    n/a
    		 0%

    Shares Change (QoQ)

    n/a
    		 0%

    Owned by Institutions (%)

    n/a
    		 n/a

    Shares Floating

    n/a
    		 n/a

    Failed to Deliver (FTD) Shares

    n/a
    		 61

    FTD / Avg. Volume

    n/a
    		 0.02%

    Short Selling Information

    Short Interest

    n/a
    		 n/a

    Short % of Shares Out

    n/a
    		 n/a

    Short % of Float

    n/a
    		 n/a

    Short Ratio (days to cover)

    n/a
    		 n/a

    Valuation Ratios

    The PE ratio is -0.25 and the forward PE ratio is null. TCR2 Therapeutics's PEG ratio is -0.01.

    PE Ratio

    n/a
    		 -0.25

    Forward PE

    n/a
    		 n/a

    PS Ratio

    n/a
    		 0

    Forward PS

    n/a
    		 n/a

    PB Ratio

    n/a
    		 0.27

    P/FCF Ratio

    n/a
    		 -0.33

    PEG Ratio

    n/a
    		 -0.01
    Financial Ratio History

    Enterprise Valuation

    TCR2 Therapeutics has an Enterprise Value (EV) of 59.6M.

    EV / Sales

    n/a
    		 0

    EV / EBITDA

    n/a
    		 -0.67

    EV / EBIT

    n/a
    		 -0.59

    EV / FCF

    n/a
    		 -0.51

    Financial Position

    The company has a current ratio of 2.77, with a Debt / Equity ratio of 0.38.

    Current Ratio

    n/a
    		 2.77

    Quick Ratio

    n/a
    		 2.77

    Debt / Equity

    n/a
    		 0.38

    Debt / EBITDA

    n/a
    		 -0.6

    Debt / FCF

    n/a
    		 -0.46

    Interest Coverage

    n/a
    		 -2.61

    Financial Efficiency

    Return on Equity is -107.78% and Return on Invested Capital is -79.01%.

    Return on Equity

    n/a
    		 -107.78%

    Return on Assets

    n/a
    		 -72.91%

    Return on Invested Capital

    n/a
    		 -79.01%

    Revenue Per Employee

    n/a
    		 n/a

    Profits Per Employee

    n/a
    		 $-2,617,620.69

    Employee Count

    n/a
    		 58

    Asset Turnover

    n/a
    		 0

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 261K

    Effective Tax Rate

    n/a
    		 -0.17%

    Stock Price Statistics

    The stock price has increased by 0% in the last 52 weeks. The beta is 1.93, so TCR2 Therapeutics's price volatility has been higher than the market average.

    Beta

    n/a
    		 1.93

    52-Week Price Change

    n/a
    		 n/a

    50-Day Moving Average

    n/a
    		 1.69

    200-Day Moving Average

    n/a
    		 1.64

    Relative Strength Index (RSI)

    n/a
    		 27.34

    Average Volume (20 Days)

    n/a
    		 325,040

    Income Statement

    Revenue

    n/a
    		 n/a

    Gross Profit

    n/a
    		 n/a

    Operating Income

    n/a
    		 -153.5M

    Net Income

    n/a
    		 -151.82M

    EBITDA

    n/a
    		 -89.62M

    EBIT

    n/a
    		 -92.67M

    Earnings Per Share (EPS)

    n/a
    		 -3.93
    Full Income Statement

    Balance Sheet

    The company has 32.75M in cash and 53.76M in debt, giving a net cash position of -21.02M.

    Cash & Cash Equivalents

    n/a
    		 32.75M

    Total Debt

    n/a
    		 53.76M

    Net Cash

    n/a
    		 -21.02M

    Retained Earnings

    n/a
    		 -501.34M

    Total Assets

    n/a
    		 151.51M

    Working Capital

    n/a
    		 93.02M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -101.46M and capital expenditures -15.45M, giving a free cash flow of -116.91M.

    Operating Cash Flow

    n/a
    		 -101.46M

    Capital Expenditures

    n/a
    		 -15.45M

    Free Cash Flow

    n/a
    		 -116.91M

    FCF Per Share

    n/a
    		 -3.03
    Full Cash Flow Statement

    Margins

    Gross Margin

    n/a
    		 n/a

    Operating Margin

    n/a
    		 n/a

    Pretax Margin

    n/a
    		 n/a

    Profit Margin

    n/a
    		 n/a

    EBITDA Margin

    n/a
    		 n/a

    EBIT Margin

    n/a
    		 n/a

    FCF Margin

    n/a
    		 n/a

    Dividends & Yields

    TCRR does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 -393.51%

    FCF Yield

    n/a
    		 -303.03%
    Dividend Details

    Analyst Forecast

    Currently there are no analyst rating for TCRR.

    Price Target

    n/a
    		 n/a

    Price Target Difference

    n/a
    		 n/a

    Analyst Consensus

    n/a
    		 n/a

    Analyst Count

    n/a
    		 n/a
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Scores

    Altman Z-Score

    n/a
    		 -7.19

    Piotroski F-Score

    n/a
    		 2

    Add to Watchlist